CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6
Get Alerts CTIC Hot Sheet
Join SI Premium – FREE
SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m. ET. The conference will be held in a virtual meeting format.
Presentation details: Event: JMP Securities Hematology & Oncology Summit Date: Monday, December 6, 2021 Time: 3:40 p.m. ET
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma Corp. We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts: Argot Partners +212-600-1902 [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology--oncology-summit-on-monday-december-6-301436710.html
SOURCE CTI BioPharma Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- COSRX Ignites TikTok with #PatThePeptide Challenge Campaign
- Intra-Cellular Therapies Prices Public Offering of Common Stock
- Empowering Female Voices: GAGA Calls on Women Worldwide for Support Meme
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JMP Securities, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!